SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Fox PT) "

Sökning: WFRF:(Fox PT)

  • Resultat 1-10 av 15
  • [1]2Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  • Campbell, PJ, et al. (författare)
  • Pan-cancer analysis of whole genomes
  • 2020
  • Ingår i: Nature. - : Nature Publishing Group. - 1476-4687 .- 0028-0836. ; 578:7793, s. 82-
  • Tidskriftsartikel (refereegranskat)
  •  
4.
  •  
5.
  • 2021
  • swepub:Mat__t
  •  
6.
  • Abazov, V. M., et al. (författare)
  • Z gamma production and limits on anomalous ZZ gamma and Z gamma gamma couplings in pp collisions at root s=1.96 TeV
  • 2007
  • Ingår i: Physics Letters B. - 0370-2693 .- 1873-2445. ; 653:5-6, s. 378-386
  • Tidskriftsartikel (refereegranskat)abstract
    • We present a study of eey and mu mu gamma events using 1109 (1009) pb-(1) of data in the electron (muon) channel, respectively. These data were collected with the DO detector at the Fermilab Tevatron pp collider at Is = 1.96 TeV. Having observed 453 (515) candidates in the eey (jtAy) final state, we measure the Z gamma production cross section for a photon with transverse energy ET > 7 GeV, separation between the photon and leptons Delta Rey > 0.7, and invariant mass of the di-lepton pair Mee > 30 GeV/(2)(c), to be 4.96 0.30(stat. + syst.) zE 0.30(lumi.) pb, in agreement with the Standard Model prediction of 4.74 0.22 pb. This is the most precise Zy cross section measurement at a hadron collider. We set limits on anomalous trilinear Zyy and ZZy gauge boson couplings of -0.085 < h(30)(y) < 0.084, -0.0053 < h(40)(y) < 0.0054 and -0.083 < h(30)(Z) < 0.082, 30 40 30 -0.0053 < h(40)(Z) < 0.0054 at the 95% C.L. for the form-factor scale A = 1.2 TeV. 40 .
  •  
7.
  •  
8.
  • Keshavan, Ashvini, et al. (författare)
  • CSF biomarkers for dementia.
  • 2022
  • Ingår i: Practical neurology. - 1474-7766.
  • Tidskriftsartikel (refereegranskat)abstract
    • Although cerebrospinal fluid (CSF) biomarker testing is incorporated into some current guidelines for the diagnosis of dementia (such as England's National Institute for Health and Care Excellence (NICE)), it is not widely accessible for most patients for whom biomarkers could potentially change management. Here we share our experience of running a clinical cognitive CSF service and discuss recent developments in laboratory testing including the use of the CSF amyloid-β 42/40 ratio and automated assay platforms. We highlight the importance of collaborative working between clinicians and laboratory staff, of preanalytical sample handling, and discuss the various factors influencing interpretation of the results in appropriate clinical contexts. We advocate for broadening access to CSF biomarkers by sharing clinical expertise, protocols and interpretation with colleagues working in psychiatry and elderly care, especially when access to CSF may be part of a pathway to disease-modifying treatments for Alzheimer's disease and other forms of dementia.
  •  
9.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 15
  • [1]2Nästa

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy